Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

[1]  F. Khuri,et al.  The care of the lung cancer patient in the 21st century: a new age. , 2004, Seminars in oncology.

[2]  Y. Shimosato.  [Histological Typing of Lung and Pleural Tumors (3rd edition, 1999): Malignant epithelial tumors]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[3]  H. Ueoka,et al.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. , 1997, International journal of radiation oncology, biology, physics.

[4]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[5]  S. Cha,et al.  Neuroendocrine differentiation is an independent prognostic factor in chemotherapy‐treated nonsmall cell lung carcinoma , 1996, Cancer.

[6]  S. Piantadosi,et al.  Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. , 1994, Chest.

[7]  F. Hirsch,et al.  Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  L. de Leij,et al.  Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Mortimer,et al.  The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  O. Dalesio,et al.  Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. , 1991, European journal of cancer.